semaglutide or retatrutide vs Semaglutide: Risks and Results Acute and chronic effects of

It'll just take a moment

June 19, 2025: Ozempic Doubles the Risk of Vision Loss from Rare Eye Condition The European Medical Agency (which functions like the FDA in the United States) has issued a chilling warning about Ozempic

In contrast to rodents, non-human primates have fewer C-cells and no measurable activation by GLP-1RAs (88)

There was a significant 24% reduction in the composite primary outcome in the semaglutide group compared with those taking placebo, with first events occurring in 5.8 versus 7.5 people per 100 person-years of follow-up, such that 20 people would need to be treated for 3 years to prevent one primary event